Fatal outcome after combined therapy for myeloblastic leukaemia and toxoplasmosis.
D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001855:Bone Marrow Diseases / Q000139:chemically induced; D003561:Cytarabine / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008297:Male; D011739:Pyrimethamine / Q000008:administration & dosage / Q000009:adverse effects*; D013418:Sulfamethazine / Q000008:administration & dosage / Q000009:adverse effects*; D014123:Toxoplasmosis / Q000188:drug therapy*
D000970:Antineoplastic Agents; D003561:Cytarabine; D013418:Sulfamethazine; D011739:Pyrimethamine; D003630:Daunorubicin